Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies
First Claim
1. A method for preventing or treating at least one of IKr channel inhibition or QT prolongation arising from administration of one or more active agents that causes an active agent-induced channelopathy in a human or animal subject comprising the steps of:
- identifying the human or animal subject in need of prevention or treatment of a disease treatable with an active agent that causes a drug-induced channelopathy;
providing an amount of a lysophosphatidyl compound adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by one or more active agents, wherein the lysophosphatidyl compound is selected from at least one of 10;
0 LysoPG, 12;
0 LysoPG, 14;
0 LysoPG, 14;
0 EGPG, 16;
0 LysoPG, or 18;
0 LysoPG, wherein the lysophosphatidyl compound enhances the activity of the active agent; and
administering to the human or animal subject a therapeutically effective amount of an active agent that causes an active agent-induced channelopathy, wherein the oral lysophosphatidyl compound reduces or eliminates the channelopathy induced by the therapeutically active agent.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidyl compound adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug. Such compositions may further comprise a monoglyceride, a free fatty acid or a combination of the foregoing, including, e.g., a eutectic mixture.
23 Citations
10 Claims
-
1. A method for preventing or treating at least one of IKr channel inhibition or QT prolongation arising from administration of one or more active agents that causes an active agent-induced channelopathy in a human or animal subject comprising the steps of:
-
identifying the human or animal subject in need of prevention or treatment of a disease treatable with an active agent that causes a drug-induced channelopathy; providing an amount of a lysophosphatidyl compound adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by one or more active agents, wherein the lysophosphatidyl compound is selected from at least one of 10;
0 LysoPG, 12;
0 LysoPG, 14;
0 LysoPG, 14;
0 EGPG, 16;
0 LysoPG, or 18;
0 LysoPG, wherein the lysophosphatidyl compound enhances the activity of the active agent; andadministering to the human or animal subject a therapeutically effective amount of an active agent that causes an active agent-induced channelopathy, wherein the oral lysophosphatidyl compound reduces or eliminates the channelopathy induced by the therapeutically active agent. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
-
10. A method for preventing or treating at least one of IKr channel inhibition or QT prolongation arising from administration of one or more active agents that causes an active agent-induced channelopathy in a human or animal subject comprising the steps of:
-
identifying the human or animal subject in need of prevention or treatment of a disease treatable with the one or more active agent that causes a drug-induced channelopathy; providing an amount of a lysophosphatidyl compound adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by one or more active agents, wherein the lysophosphatidyl compound is selected from at least one of 10;
0 LysoPG, 12;
0 LysoPG, 14;
0 LysoPG, 14;
0 EGPG, 16;
0 LysoPG, 18;
0 LysoPG, or a eutectic thereof, wherein the lysophosphatidyl compound enhances the activity of the active agent; andadministering to the human or animal subject a therapeutically effective amount of an active agent that causes an active agent-induced channelopathy, wherein the oral lysophosphatidyl compound reduces or eliminates the channelopathy induced by the therapeutically active agent.
-
Specification